Companies / Sanofi
Sanofi
CompanySanofi is a French multinational pharmaceutical and healthcare company headquartered in Paris. The company was established in 1973 and now trades on Euronext Paris and Nasdaq.
- Trials
- 1543
- Recruiting
- 77
- Completed
- 1195
- With results
- 302
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 | 5 | 1 | — | 3 | 202 | 16 | 2 | — | — | — | — | — | 229 |
| Phase 1/2 | 8 | — | — | 3 | 20 | 18 | — | — | — | — | — | — | 49 |
| Phase 2 | 14 | 2 | 3 | 19 | 212 | 48 | 6 | 1 | — | — | — | — | 305 |
| Phase 2/3 | 1 | — | — | 1 | 13 | — | — | — | — | — | — | — | 15 |
| Phase 3 | 21 | 2 | 2 | 23 | 437 | 64 | 4 | — | 1 | — | — | — | 554 |
| Phase 4 | 5 | 1 | — | 5 | 246 | 23 | 1 | — | — | — | — | — | 281 |
| Not applicable | 1 | — | — | — | 6 | — | — | — | — | — | — | — | 7 |
| Unknown | 22 | 2 | — | 11 | 59 | 6 | — | — | — | 1 | 1 | 1 | 103 |
Trials started per year
Conditions studied, by phase
| Condition | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | 16 | — | 8 | — | 79 | 75 | 1 | 5 | 184 |
| Diabetes Mellitus, Type 1 | 18 | 1 | 4 | — | 18 | 14 | 1 | 5 | 61 |
| Neoplasms | 36 | 6 | 7 | — | 6 | 3 | 1 | 1 | 60 |
| Asthma | 1 | — | 11 | — | 16 | 4 | — | 5 | 37 |
| Hypercholesterolemia | 9 | — | 5 | — | 22 | 1 | — | — | 37 |
| Dermatitis, Atopic | 1 | — | 5 | 2 | 7 | 7 | — | 14 | 36 |
| Diabetes Mellitus | 7 | — | 2 | — | 12 | 10 | 1 | 1 | 33 |
| Breast Neoplasms | 3 | 4 | 14 | — | 10 | — | — | 1 | 32 |
| Hypertension | — | — | 1 | 1 | 6 | 20 | — | 1 | 29 |
| Arthritis, Rheumatoid | 8 | 1 | 3 | 1 | 9 | 4 | — | 1 | 27 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Sanofi | 1543 | 569 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | Regeneron Pharmaceuticals | 152 |
| 2 | Bristol-Myers Squibb | 35 |
| 3 | Procter and Gamble | 11 |
| 4 | Hanmi Pharmaceutical Company Limited | 4 |
| 5 | Merck Sharp & Dohme LLC | 4 |
| 6 | Teva Branded Pharmaceutical Products R&D LLC | 4 |
| 7 | Cancer International Research Group (CIRG) | 3 |
| 8 | Kymera Therapeutics, Inc. | 3 |
| 9 | Medicines for Malaria Venture | 3 |
| 10 | Genzyme, a Sanofi Company | 2 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Insulin Glargine | 143 |
| 2 | Docetaxel | 66 |
| 3 | dupilumab | 65 |
| 4 | Metformin | 56 |
| 5 | insulin glulisine | 45 |
| 6 | lixisenatide | 45 |
| 7 | Oxaliplatin | 39 |
| 8 | Lactic Acid | 37 |
| 9 | alirocumab | 36 |
| 10 | Rimonabant | 35 |
Evidence
- Results reported
- 25.3%302 of 1195 completed
- Published
- 14.3%171 of 1195 completed
- Primary endpoint met
- 66.5%165 of 248 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 148
- Median duration
- 22months
- Countries
- 106
- Study sites
- 29805
Who is enrolled
Median enrollment by phase
- Phase 1
- 34
- Phase 1/2
- 46
- Phase 2
- 100
- Phase 2/3
- 568
- Phase 3
- 366
- Phase 4
- 179
- Not applicable
- 239
- Unknown
- 303
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Paris | France | 278 |
| 2 | Barcelona | Spain | 274 |
| 3 | Berlin | Germany | 230 |
| 4 | Milan | Italy | 230 |
| 5 | São Paulo | Brazil | 222 |
| 6 | Bridgewater | United States | 221 |
| 7 | Prague | Czechia | 189 |
| 8 | Moscow | Russia | 184 |
| 9 | Santiago | Chile | 180 |
| 10 | Warsaw | Poland | 177 |
Terminations
- Terminated
- 175
- Withdrawn
- 13
- Suspended
- 1
- Stopped for recruitment
- 2.1%32 of 1543 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07547436 Suspended | Suspended | The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity. | 2029-05-11 |
| NCT07484230 Withdrawn | Withdrawn | Sponsor decision. Not related to safety concern. | 2028-10-10 |
| NCT05726682 Withdrawn | Withdrawn | Sponsor decision to cancel trial, not related to safety concern. | 2027-10-11 |
| NCT07316114 Terminated | Terminated | Sponsor decision; the decision is not related to any safety concern. | 2026-06-02 |
| NCT06444451 Terminated | Terminated | Sponsor decision; the decision is not related to any safety concern | 2026-05-21 |
| NCT04401020 Terminated | Terminated | Sponsor decision based on limited clinical benefit observed in both Multiple Myeloma and Non-Hodgkin Lymphoma cohorts | 2026-05-11 |
| NCT04154956 Terminated | Terminated | Sponsor decision, the decision is not related to any safety concern. | 2026-04-16 |
| NCT05450562 Terminated | Terminated | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | 2025-12-22 |
| NCT06058156 Terminated | Terminated | Sponsor decision. Not related to safety concern. | 2025-11-20 |
| NCT06028230 Terminated | Terminated | Sponsor decision. Not related to safety concern. | 2025-11-12 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: